Estrogen metabolite 16α-hydroxyestrone exacerbates bone morphogenetic protein receptor Type II-associated pulmonary arterial hypertension through MicroRNA-29-mediated modulation of cellular metabolism

Circulation

Volumn 133, Issue 1, 2016, Pages 82-97

  Chen, Xinping ^a   Talati, Megha ^a   Fessel, Joshua P ^a,b   Hemnes, Anna R ^a   Gladson, Santhi ^a   French, Jaketa ^a   Shay, Sheila ^a   Trammell, Aaron ^c   Phillips, John A ^a   Hamid, Rizwan ^a   Cogan, Joy D ^a   Dawson, Elliott P ^d   Womble, Kristie E ^d   Hedges, Lora K ^a   Martinez, Elizabeth G ^a   Wheeler, Lisa A ^a   Loyd, James E ^a   Majka, Susan J ^a   West, James ^a   Austin, Eric D ^e  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d BioVentures Inc   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

estrogens; hypertension, pulmonary; metabolism; microRNAs; models, animal

Indexed keywords

16ALPHA HYDROXYESTRONE; ANTAGOMIR; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CD36 ANTIGEN; ENDOTHELIN RECEPTOR ANTAGONIST; LNA MICRORNA29 ANTIBODY; MICRORNA; MICRORNA 29; MICRORNA 29A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID; RNA ANTIBODY; UNCLASSIFIED DRUG; 16-HYDROXYESTRONE; BMPR2 PROTEIN, HUMAN; ESTRONE DERIVATIVE; MIRN29 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE REPORT; CELL METABOLISM; CONTROLLED STUDY; DISEASE EXACERBATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOTHELIUM CELL; ENERGY METABOLISM; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INSULIN RESISTANCE; LUNG PARENCHYMA; LUNG VASCULAR RESISTANCE; MALE; METABOLIC DISORDER; METABOLIC REGULATION; MICROARRAY ANALYSIS; MITOCHONDRIAL VOLUME; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL LINE; PRIORITY JOURNAL; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; RNA FINGERPRINTING; TRANSGENIC MOUSE; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; HYPERTENSION, PULMONARY; METABOLISM; PHYSIOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CELLULAR MICROENVIRONMENT; FEMALE; HUMANS; HYDROXYESTRONES; HYPERTENSION, PULMONARY; MALE; MICE; MICE, TRANSGENIC; MICRORNAS;

EID: 84953835406     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.016133     Document Type: Article

References (88)

1. Tuder RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C, Michelakis E, Rabinovitch M, Schermuly R, Stenmark KR, Morrell NW., Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013 62 suppl D4 12. doi: 10.1016/j.jacc.2013.10.025.
2. Austin ED, Lahm T, West J, Tofovic SP, Johansen AK, Maclean MR, Alzoubi A, Oka M., Gender, sex hormones and pulmonary hypertension. Pulm Circ 2013 3 294 314. doi: 10.4103/2045-8932.114756.
3. Austin ED, Loyd JE., The genetics of pulmonary arterial hypertension. Circ Res 2014 115 189 202. doi: 10.1161/CIRCRESAHA.115.303404.
4. Chin KM, Rubin LJ., Pulmonary arterial hypertension. J Am Coll Cardiol 2008 51 1527 1538. doi: 10.1016/j.jacc.2008.01.024.
5. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G., Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006 173 1023 1030. doi: 10.1164/rccm.200510-1668OC.
6. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD., Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010 137 376 387. doi: 10.1378/chest.09-1140.
7. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaïci A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jaïs X, Montani D, Souza R, Simonneau G., Survival in patients with idiopathic, familial, and anorexigen-Associated pulmonary arterial hypertension in the modern management era. Circulation 2010 122 156 163. doi: 10.1161/CIRCULATIONAHA.109.911818.
8. Mair KM, Wright AF, Duggan N, Rowlands DJ, Hussey MJ, Roberts S, Fullerton J, Nilsen M, Loughlin L, Thomas M, MacLean MR., Sex-Dependent influence of endogenous estrogen in pulmonary hypertension. Am J Respir Crit Care Med 2014 190 456 467. doi: 10.1164/rccm.201403-0483OC.
9. White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, Campbell A, Morecroft I, Loughlin L, McClure JD, Thomas M, Mair KM, MacLean MR., Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation 2012 126 1087 1098. doi: 10.1161/CIRCULATIONAHA.111.062927.
10. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR., The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res 2011 90 373 382. doi: 10.1093/cvr/cvq408.
11. Dempsie Y, MacRitchie NA, White K, Morecroft I, Wright AF, Nilsen M, Loughlin L, Mair KM, MacLean MR., Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension. Cardiovasc Res 2013 99 24 34. doi: 10.1093/cvr/cvt064.
12. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, Wheeler LA, Parl FF, Loyd JE, Phillips JA 3rd., Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J 2009 34 1093 1099. doi: 10.1183/09031936.00010409.
13. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, Tighiouart H, Knowles JA, Rabinowitz D, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Kawut SM, Pulmonary Vascular Complications of Liver Disease Study Group Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009 179 835 842. doi: 10.1164/rccm.200809-1472OC.
14. West J, Cogan J, Geraci M, Robinson L, Newman J, Phillips JA, Lane K, Meyrick B, Loyd J., Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics 2008 1 45. doi: 10.1186/1755-8794-1-45.
15. Sweeney L, Voelkel NF., Estrogen exposure, obesity and thyroid disease in women with severe pulmonary hypertension. Eur J Med Res 2009 14 433 442
16. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE., Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev 1995 4 649 654
17. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Corbin CJ, Mendelson CR., Tissue-specific promoters regulate aromatase cytochrome P450 expression. J Steroid Biochem Mol Biol 1993 44 321 330
18. West J, Cogan J, Geraci M, Robinson L, Newman J, Phillips JA, Lane K, Meyrick B, Loyd J., Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics 2008 1 45. doi: 10.1186/1755-8794-1-45.
19. Hemnes AR, Brittain EL, Trammell AW, Fessel JP, Austin ED, Penner N, Maynard KB, Gleaves L, Talati M, Absi T, Disalvo T, West J., Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2014 189 325 334. doi: 10.1164/rccm.201306-1086OC.
20. Fessel JP, Flynn CR, Robinson LJ, Penner NL, Gladson S, Kang CJ, Wasserman DH, Hemnes AR, West JD., Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension. Am J Respir Cell Mol Biol 2013 49 778 787. doi: 10.1165/rcmb.2012-0463OC.
21. West J, Niswender KD, Johnson JA, Pugh ME, Gleaves L, Fessel JP, Hemnes AR., A potential role for insulin resistance in experimental pulmonary hypertension. Eur Respir J 2013 41 861 871. doi: 10.1183/09031936.00030312.
22. Fessel JP, Chen X, Frump A, Gladson S, Blackwell T, Kang C, Johnson J, Loyd JE, Hemnes A, Austin E, West J., Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension. Pulm Circ 2013 3 564 577. doi: 10.1086/674312.
23. Caja S, Puerta M., Control by reproduction-related hormones of resistin expression and plasma concentration. Horm Metab Res 2007 39 501 506. doi: 10.1055/s-2007-982515.
24. Lee MJ, Lin H, Liu CW, Wu MH, Liao WJ, Chang HH, Ku HC, Chien YS, Ding WH, Kao YH., Octylphenol stimulates resistin gene expression in 3T3-L1 adipocytes via the estrogen receptor and extracellular signal-regulated kinase pathways. Am J Physiol Cell Physiol 2008 294 C1542 C1551. doi: 10.1152/ajpcell.00403.2007.
25. Marsboom G, Toth PT, Ryan JJ, Hong Z, Wu X, Fang YH, Thenappan T, Piao L, Zhang HJ, Pogoriler J, Chen Y, Morrow E, Weir EK, Rehman J, Archer SL., Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res 2012 110 1484 1497. doi: 10.1161/CIRCRESAHA.111.263848.
26. Fessel JP, Hamid R, Wittmann BM, Robinson LJ, Blackwell T, Tada Y, Tanabe N, Tatsumi K, Hemnes AR, West JD., Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Pulm Circ 2012 2 201 213. doi: 10.4103/2045-8932.97606.
27. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, Rabinovitch M., Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-Activated receptor-gamma activation. Circulation 2007 115 1275 1284. doi: 10.1161/CIRCULATIONAHA.106.663120.
28. Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, Rabinovitch M, Doyle RL., Insulin resistance in pulmonary arterial hypertension. Eur Respir J 2009 33 318 324. doi: 10.1183/09031936.00000508.
29. Pugh ME, Robbins IM, Rice TW, West J, Newman JH, Hemnes AR., Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant 2011 30 904 911. doi: 10.1016/j.healun.2011.02.016.
30. Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes KD, Lopaschuk GD, Dyck JR, Michelakis ED., Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med 2010 2 44ra58. doi: 10.1126/scitranslmed.3001327.
31. Bagge A, Clausen TR, Larsen S, Ladefoged M, Rosenstierne MW, Larsen L, Vang O, Nielsen JH, Dalgaard LT., MicroRNA-29a is up-regulated in beta-cells by glucose and decreases glucose-stimulated insulin secretion. Biochem Biophys Res Commun 2012 426 266 272. doi: 10.1016/j.bbrc.2012.08.082.
32. Kurtz CL, Peck BC, Fannin EE, Beysen C, Miao J, Landstreet SR, Ding S, Turaga V, Lund PK, Turner S, Biddinger SB, Vickers KC, Sethupathy P., MicroRNA-29 fine-Tunes the expression of key FOXA2-Activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes 2014 63 3141 3148. doi: 10.2337/db13-1015.
33. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R., Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013 62 suppl D34 D41. doi: 10.1016/j.jacc.2013.10.029.
34. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011 183 788 824. doi: 10.1164/rccm.2009-040GL.
35. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A, Smyth GK., A comparison of background correction methods for two-colour microarrays. Bioinformatics 2007 23 2700 2707. doi: 10.1093/bioinformatics/btm412.
36. Chang CC, Lin CC, Hsieh WL, Lai HW, Tsai CH, Cheng YW., MicroRNA expression profiling in PBMCs: a potential diagnostic biomarker of chronic hepatitis C. Dis Markers 2014 2014 367157. doi: 10.1155/2014/367157.
37. Lv LL, Cao YH, Ni HF, Xu M, Liu D, Liu H, Chen PS, Liu BC., MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis. Am J Physiol Renal Physiol 2013 305 F1220 F1227. doi: 10.1152/ajprenal.00148.2013.
38. Ørom UA, Lund AH., Experimental identification of microRNA targets. Gene 2010 451 1 5. doi: 10.1016/j.gene.2009.11.008.
39. Orom UA, Lund AH., Isolation of microRNA targets using biotinylated synthetic microRNAs. Methods 2007 43 162 165. doi: 10.1016/j.ymeth.2007.04.007.
40. Kedde M, Strasser MJ, Boldajipour B, Oude Vrielink JA, Slanchev K, le Sage C, Nagel R, Voorhoeve PM, van Duijse J, Ørom UA, Lund AH, Perrakis A, Raz E, Agami R., RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell 2007 131 1273 1286. doi: 10.1016/j.cell.2007.11.034.
41. Ørom UA, Nielsen FC, Lund AH., MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008 30 460 471. doi: 10.1016/j.molcel.2008.05.001.
42. Ott CE, Grünhagen J, Jäger M, Horbelt D, Schwill S, Kallenbach K, Guo G, Manke T, Knaus P, Mundlos S, Robinson PN., MicroRNAs differentially expressed in postnatal aortic development downregulate elastin via 3' UTR and coding-sequence binding sites. PLoS One 2011 6 e16250. doi: 10.1371/journal.pone.0016250.
43. Kurtz CL, Peck BC, Fannin EE, Beysen C, Miao J, Landstreet SR, Ding S, Turaga V, Lund PK, Turner S, Biddinger SB, Vickers KC, Sethupathy P., MicroRNA-29 fine-Tunes the expression of key FOXA2-Activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes 2014 63 3141 3148. doi: 10.2337/db13-1015.
44. Yasuda T, Tada Y, Tanabe N, Tatsumi K, West J., Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene. Am J Physiol Lung Cell Mol Physiol 2011 301 L667 L674. doi: 10.1152/ajplung.00423.2010.
45. Johnson JA, Hemnes AR, Perrien DS, Schuster M, Robinson LJ, Gladson S, Loibner H, Bai S, Blackwell TR, Tada Y, Harral JW, Talati M, Lane KB, Fagan KA, West J., Cytoskeletal defects in Bmpr2-Associated pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2012 302 L474 L484. doi: 10.1152/ajplung.00202.2011.
46. West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder R, Rodman DM., Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 2004 94 1109 1114. doi: 10.1161/01.RES.0000126047.82846.20.
47. West J, Harral J, Lane K, Deng Y, Ickes B, Crona D, Albu S, Stewart D, Fagan K., Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am J Physiol Lung Cell Mol Physiol 2008 295 L744 L755. doi: 10.1152/ajplung.90255.2008.
48. Lustig RH, Mobbs CV, Bradlow HL, McEwen BS, Pfaff DW., Differential effects of estradiol and 16 alpha-hydroxyestrone on pituitary and preoptic estrogen receptor regulation. Endocrinology 1989 125 2701 2709. doi: 10.1210/endo-125-5-2701.
49. West JD, Austin ED, Gaskill C, Marriott S, Baskir R, Bilousova G, Jean JC, Hemnes AR, Menon S, Bloodworth NC, Fessel JP, Kropski JA, Irwin D, Ware LB, Wheeler L, Hong CC, Meyrick B, Loyd JE, Bowman AB, Ess KC, Klemm DJ, Young PP, Merryman WD, Kotton D, Majka SM., Identification of a common Wnt-Associated genetic signature across multiple cell types in pulmonary arterial hypertension. Am J Physiol Cell Physiol 2014 307 C415 C430. doi: 10.1152/ajpcell.00057.2014.
50. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412 419
51. Muniyappa R, Lee S, Chen H, Quon MJ., Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008 294 E15 E26. doi: 10.1152/ajpendo.00645.2007.
52. Radziuk J., Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2000 85 4426 4433. doi: 10.1210/jcem.85.12.7025.
53. Hudson WH, Ortlund EA., The structure, function and evolution of proteins that bind DNA and RNA. Nat Rev Mol Cell Biol 2014 15 749 760. doi: 10.1038/nrm3884.
54. Qin W, Chung AC, Huang XR, Meng XM, Hui DS, Yu CM, Sung JJ, Lan HY., TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 2011 22 1462 1474. doi: 10.1681/ASN.2010121308.
55. Wang B, Komers R, Carew R, Winbanks CE, Xu B, Herman-Edelstein M, Koh P, Thomas M, Jandeleit-Dahm K, Gregorevic P, Cooper ME, Kantharidis P., Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol 2012 23 252 265. doi: 10.1681/ASN.2011010055.
56. Long SD, Pekala PH., Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem J 1996 319 (Pt 1) 179 184
57. Archer SL, Gomberg-Maitland M, Maitland ML, Rich S, Garcia JG, Weir EK., Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 2008 294 H570 H578. doi: 10.1152/ajpheart.01324.2007.
58. Rehman J, Archer SL., A proposed mitochondrial-metabolic mechanism for initiation and maintenance of pulmonary arterial hypertension in fawn-hooded rats: the Warburg model of pulmonary arterial hypertension. Adv Exp Med Biol 2010 661 171 185. doi: 10.1007/978-1-60761-500-2-11.
59. Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, Janocha AJ, Masri FA, Arroliga AC, Jennings C, Dweik RA, Tuder RM, Stuehr DJ, Erzurum SC., Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A 2007 104 1342 1347. doi: 10.1073/pnas.0605080104.
60. Ong SB, Hausenloy DJ., Mitochondrial morphology and cardiovascular disease. Cardiovasc Res 2010 88 16 29. doi: 10.1093/cvr/cvq237.
61. Archer SL., Mitochondrial dynamics: mitochondrial fission and fusion in human diseases. N Engl J Med 2013 369 2236 2251. doi: 10.1056/NEJMra1215233.
62. Zolezzi JM, Silva-Alvarez C, Ordenes D, Godoy JA, Carvajal FJ, Santos MJ, Inestrosa NC., Peroxisome proliferator-Activated receptor (PPAR) γ and PPAR agonists modulate mitochondrial fusion-fission dynamics: relevance to reactive oxygen species (ROS)-related neurodegenerative disorders? PLoS One 2013 8 e64019. doi: 10.1371/journal.pone.0064019.
63. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB., Effects of low doses of transdermal 17 beta-Estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992 74 1396 1400. doi: 10.1210/jcem.74.6.1317387.
64. Godsland IF, Walton C, Felton C, Proudler A, Patel A, Wynn V., Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1992 74 64 70. doi: 10.1210/jcem.74.1.1530790.
65. Watanabe RM, Azen CG, Roy S, Perlman JA, Bergman RN., Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. J Clin Endocrinol Metab 1994 79 1277 1283. doi: 10.1210/jcem.79.5.7962320.
66. de Lauzon-Guillain B, Fournier A, Fabre A, Simon N, Mesrine S, Boutron-Ruault MC, Balkau B, Clavel-Chapelon F., Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l'Education Nationale (E3N) cohort. Diabetologia 2009 52 2092 2100. doi: 10.1007/s00125-009-1456-y.
67. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T., Identification of novel genes coding for small expressed RNAs. Science 2001 294 853 858. doi: 10.1126/science.1064921.
68. Bartel DP., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 116 281 297
69. Koch L., Disease genetics: insights into missing heritability. Nat Rev Genet 2014 15 218. doi: 10.1038/nrg3713.
70. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J, Simard MJ, Bonnet S., Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011 208 535 548. doi: 10.1084/jem.20101812.
71. Kim J, Kang Y, Kojima Y, Lighthouse JK, Hu X, Aldred MA, McLean DL, Park H, Comhair SA, Greif DM, Erzurum SC, Chun HJ., An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med 2013 19 74 82. doi: 10.1038/nm.3040.
72. Drake KM, Zygmunt D, Mavrakis L, Harbor P, Wang L, Comhair SA, Erzurum SC, Aldred MA., Altered MicroRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8. Am J Respir Crit Care Med 2011 184 1400 1408. doi: 10.1164/rccm.201106-1130OC.
73. Caruso P, Dempsie Y, Stevens HC, McDonald RA, Long L, Lu R, White K, Mair KM, McClure JD, Southwood M, Upton P, Xin M, van Rooij E, Olson EN, Morrell NW, MacLean MR, Baker AH., A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res 2012 111 290 300. doi: 10.1161/CIRCRESAHA.112.267591.
74. Parikh VN, Jin RC, Rabello S, Gulbahce N, White K, Hale A, Cottrill KA, Shaik RS, Waxman AB, Zhang YY, Maron BA, Hartner JC, Fujiwara Y, Orkin SH, Haley KJ, Barabási AL, Loscalzo J, Chan SY., MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 2012 125 1520 1532. doi: 10.1161/CIRCULATIONAHA.111.060269.
75. Jalali S, Ramanathan GK, Parthasarathy PT, Aljubran S, Galam L, Yunus A, Garcia S, Cox RR Jr, Lockey RF, Kolliputi N., Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. PLoS One 2012 7 e46808. doi: 10.1371/journal.pone.0046808.
76. Wang D, Zhang H, Li M, Frid MG, Flockton AR, McKeon BA, Yeager ME, Fini MA, Morrell NW, Pullamsetti SS, Velegala S, Seeger W, McKinsey TA, Sucharov CC, Stenmark KR., MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res 2014 114 67 78. doi: 10.1161/CIRCRESAHA.114.301633.
77. Rhodes CJ, Wharton J, Boon RA, Roexe T, Tsang H, Wojciak-Stothard B, Chakrabarti A, Howard LS, Gibbs JS, Lawrie A, Condliffe R, Elliot CA, Kiely DG, Huson L, Ghofrani HA, Tiede H, Schermuly R, Zeiher AM, Dimmeler S, Wilkins MR., Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013 187 294 302. doi: 10.1164/rccm.201205-0839OC.
78. Paulin R, Sutendra G, Gurtu V, Dromparis P, Haromy AS, Provencher S, Bonnet S, Michelakis ED., A miR-208-Mef2 axis drives the de-compensation of right ventricular function in pulmonary hypertension. Circ Res 2015 116 56 69. doi: 10.1161/CIRCRESAHA.115.303910.
79. Rask-Madsen C, King GL., Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab 2013 17 20 33. doi: 10.1016/j.cmet.2012.11.012.
80. Swaneck GE, Fishman J., Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci U S A 1988 85 7831 7835
81. Baran-Gale J, Fannin EE, Kurtz CL, Sethupathy P., Beta cell 5'-shifted isomiRs are candidate regulatory hubs in type 2 diabetes. PLoS One 2013 8 e73240. doi: 10.1371/journal.pone.0073240.
82. Li C, Hung Wong W., Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol 2001 2 RESEARCH0032
83. Pullen TJ, da Silva Xavier G, Kelsey G, Rutter GA., miR-29a and miR-29b contribute to pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (Mct1). Mol Cell Biol 2011 31 3182 3194. doi: 10.1128/MCB.01433-10.
84. Zhang Y, Wu L, Wang Y, Zhang M, Li L, Zhu D, Li X, Gu H, Zhang CY, Zen K., Protective role of estrogen-induced miRNA-29 expression in carbon tetrachloride-induced mouse liver injury. J Biol Chem 2012 287 14851 14862. doi: 10.1074/jbc.M111.314922.
85. Steneberg P, Sykaras AG, Backlund F, Straseviciene J, Söderström I, Edlund H., Hyperinsulinemia enhances hepatic expression of the fatty acid transporter Cd36 and provokes hepatosteatosis and hepatic insulin resistance. J Biol Chem 2015 290 19034 19043. doi: 10.1074/jbc.M115.640292.
86. Armoni M, Harel C, Karnieli E., Transcriptional regulation of the GLUT4 gene: from PPAR-gamma and FOXO1 to FFA and inflammation. Trends Endocrinol Metab 2007 18 100 107. doi: 10.1016/j.tem.2007.02.001.
87. Humbert M, Sitbon O, Yaïci A, Montani D, O'Callaghan DS, Jaïs X, Parent F, Savale L, Natali D, Günther S, Chaouat A, Chabot F, Cordier JF, Habib G, Gressin V, Jing ZC, Souza R, Simonneau G, French Pulmonary Arterial Hypertension Network Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010 36 549 555. doi: 10.1183/09031936.00057010.
88. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD., Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010 122 164 172. doi: 10.1161/CIRCULATIONAHA.109.898122.